Jun 04, 2014  We evaluated the residual risk of recurrence and prognostic factors of 2838 patients with stage IIII breast cancer who were treated with AST between January 1, 1985, and November 1, 2001, and remained disease free for 5 years. Residual recurrencefree survival was estimated from the landmark of 5 years after AST to date of first recurrence or last followup using the KaplanMeier